Zydus Lifesciences Limited - Balance (Quarterly)

Zydus Lifesciences Limited
IN ˙ BSE
927,15 ₹ ↓ -19,95 (-2,11%)
2026-04-24
DEL PRIS
Balance (Quarterly)

Zydus Lifesciences Limited Balance viser kontosaldi for virksomheden på tidspunkter. Balancedata inkluderer aktiver, omsætningsaktiver, anlægsaktiver, materielle anlægsaktiver (PPE), inventar, immaterielle aktiver, passiver, kortfristede forpligtelser, gæld, kapitalleasingforpligtelser, almindelige aktier, overført overskud, egne aktier og egenkapital.

Alle tal er gange 1,000,000.00 undtagen pr. andel enheder.

2021
09-30
2022
03-31
2022
09-30
2023
03-31
2023
09-30
2024
03-31
2024
09-30
2025
03-31
2025
09-30
Kontanter 6.457 11.069 7.837 5.731 9.071 11.051 15.936 8.268 27.825
Ændring (%) 71,43 -29,20 -26,87 58,28 21,83 44,20 -48,12 236,54
Aktiver Nuværende 123.980 120.952 97.115 100.082 99.348 115.014 121.569 170.461 183.129
Ændring (%) -2,44 -19,71 3,06 -0,73 15,77 5,70 40,22 7,43
Aktiver 274.712 277.954 256.293 257.564 258.794 292.808 314.459 372.017 468.973
Ændring (%) 1,18 -7,79 0,50 0,48 13,14 7,39 18,30 26,06
Forpligtelser 92.956 87.416 68.618 60.681 49.385 71.792 72.913 108.433 188.074
Ændring (%) -5,96 -21,50 -11,57 -18,62 45,37 1,56 48,72 73,45
Egenkapital 181.756 190.538 187.675 196.883 209.409 221.016 241.546 263.584 280.899
Ændring (%) 4,83 -1,50 4,91 6,36 5,54 9,29 9,12 6,57
Passiver og Aktiekapital 274.712 277.954 256.293 257.564 258.794 292.808 314.459 372.017 468.973
Ændring (%) 1,18 -7,79 0,50 0,48 13,14 7,39 18,30 26,06

Source: Capital IQ

Other Listings
IN:ZYDUSLIFE 927,15 ₹
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista